胃食管领域中国力量崛起！2025 ASCO GI最值得关注的研究亮点

１2.　摘要号：375

标题：Envafolimab in combination with lenvatinib and albumin paclitaxel for previously treated advanced GEJ adenocarcinoma: Latest analysis of a phase II, two-cohort study.

Envafolimab 联合仑伐替尼和白蛋白紫杉醇治疗既往治疗的晚期胃食管结合部腺癌：Ⅱ期双队列研究的最新分析

讲者：赵晓莹 复旦大学附属肿瘤医院

13.　摘要号：390

标题：An exploratory phase II trial of low-dose decitabine and sintilimab combined with chemotherapy in HER2-negative gastric or gastroesophageal junction adenocarcinoma.

低剂量地西他滨和信迪利单抗联合化疗治疗HER2阴性胃/胃食管结合部腺癌的探索性Ⅱ期试验

讲者：杜云毅 长治市人民医院

14.　摘要号：392

标题：First-line (1L) nivolumab (NIVO) plus chemotherapy (chemo) vs chemo in patients (pts) with advanced gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma (GC/GEJC/EAC): 5-year (y) follow-up of Chinese pts from CheckMate 649.

一线纳武利尤单抗 (NIVO) 加化疗对比单纯化疗治疗晚期胃/胃食管结合部腺癌及食管腺癌 (GC/GEJC/EAC) 患者：CheckMate-649研究中国患者的5年随访结果

讲者：沈琳 北京肿瘤医院

15.　摘要号：396

标题：Perioperative chemotherapy with either S-1 or 5-fluorouracil plus oxaliplatin and docetaxel for locally advanced gastric or gastroesophageal junction adenocarcinoma: A prospective trial and matched comparison.

采用S-1或5-氟尿嘧啶联合奥沙利铂和多西他赛治疗对局部晚期胃/胃食管结合部腺癌进行围手术期化疗：一项前瞻性试验及匹配对照研究

讲者：颜志杰 国立成功大学医学院附属医院

16.　摘要号：406

标题：PD-1 inhibitor (sintilimab) and fruquintinib plus SOX as conversion therapy for initially unresectable gastric/gastroesophageal junction adenocarcinoma (GC/GEJC): Updated results from a single-arm, phase 2 clinical trial.

PD-1抑制剂（信迪利单抗）与呋喹替尼联合SOX方案作为初始不可切除胃/胃食管结合部腺癌（GC/GEJC）转化治疗：一项单臂、Ⅱ期临床试验的最新结果

讲者：马飞 河南省肿瘤医院

17.　摘要号：407

标题：A phase Ⅱ study of fruquintinib plus sintilimab as a second-line therapy for advanced gastric and gastroesophageal junction adenocarcinoma (GC/GEJC): Updated results.

呋喹替尼联合信迪利单抗作为晚期胃/胃食管结合部腺癌（GC/GEJC）二线治疗的Ⅱ期研究最新结果

讲者：金敏 华中科技大学同济医学院附属协和医院

18.　摘要号：423

标题：Updated results from the phase Ib/Ⅱ study of fruquintinib combined with SOX and toripalimab in patients with advanced metastatic gastric/gastroesophageal junction adenocarcinoma (GC/GEJC).

呋喹替尼联合SOX方案和特瑞普利单抗治疗晚期转移性胃/胃食管结合部腺癌患者的Ⅰb/Ⅱ期研究最新结果

讲者：孟祥瑞 郑州大学第一附属医院

19.　摘要号：414

标题：Tislelizumab (TIS) + chemotherapy (chemo) vs placebo (PBO) + chemo as first-line (1L) treatment in gastric/gastroesophageal junction adenocarcinoma (GC/GEJC) patients with/without peritoneal or liver metastases: A post hoc analysis of RATIONALE-305 study.

替雷利珠单抗(TIS)+化疗(chemo) vs. 安慰剂(PBO)+化疗一线(1L)治疗伴/不伴腹膜转移或肝转移的胃/胃食管结合部腺癌 (GC/GEJC) 患者的疗效：RATIONALE-305研究的事后分析

讲者：邱妙珍 中山大学肿瘤防治中心

20.　摘要号：431

标题：FG-M108 plus capecitabine and oxaliplatin (CAPOX) for first-line treatment of CLDN18.2+/HER2- advanced gastric/gastroesophageal junction adenocarcinoma (GC): Update results of a phase Ⅰ/Ⅱ trial to determine RP2D.

FG-M108联合卡培他滨和奥沙利铂 (CAPOX) 一线治疗CLDN18.2+/HER2-晚期胃/胃食管结合部腺癌：旨在确定RP2D的Ⅰ/Ⅱ期试验的最新结果

讲者：龚继芳 北京肿瘤医院

21.　摘要号：440

标题：HLX22 plus trastuzumab and XELOX for first-line treatment of HER2-positive locally advanced or metastatic gastric/gastroesophageal junction cancer (G/GEJC): Updated results with additional patients.

HLX22联合曲妥珠单抗和XELOX用于HER2阳性局部晚期或转移性胃/胃食管结合部腺癌（G/GEJC）的一线治疗：新增患者的最新研究结果

讲者：李进 上海高博肿瘤医院

22.　摘要号：444

标题：Preliminary results of benmelstobart plus anlotinib combined with SOX in the first-line treatment of advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma with low PD-L1 expression: A single-arm, multicenter phase II clinical trial.

贝莫苏拜单抗联合安罗替尼和SOX方案一线治疗PD-L1低表达的晚期胃/胃食管结合部腺癌的单臂、多中心、Ⅱ期临床研究初步结果

讲者：贾永旭 郑州大学第一附属医院

23.　摘要号：454

标题：Updated efficacy results of ASKB589 combined with CAPOX and PD-1 inhibitor as first-line treatment for metastatic gastric/gastro-esophageal junction (G/GEJ) adenocarcinoma from a phase Ib/II study.

ASKB589联合CAPOX和PD-1抑制剂作为转移性胃/胃食管结合部腺癌 (G/GEJ) 一线治疗的Ⅰb/Ⅱ期研究的最新疗效结果

讲者：彭智 北京肿瘤医院

24.　摘要号：450

标题：Tislelizumab (Tisle) combined with POFI (irinotecan, paclitaxel, oxaliplatin and 5-FU/levoleucovorin) as first-line treatment of advanced gastric/gastroesophageal junction adenocarcinoma (AGC): OS analysis results of the SYLT-023.

替雷利珠单抗（Tisle）联合 POFI（伊立替康、紫杉醇、奥沙利铂和 5-FU/左旋亚叶酸）作为晚期胃/胃食管结合部腺癌（AGC）的一线治疗：SYLT-023 的总生存期分析结果

讲者：苏丽玉 福建省肿瘤医院

25.　摘要号：461

标题：Fruquintinib combined with PD-1 inhibitors and chemotherapy in the first-line treatment of HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma (FDZL-FIX): A single-arm, open-label phase 2 study.

呋喹替尼联合PD-1抑制剂和化疗一线治疗HER2阴性晚期胃癌/胃食管结合部腺癌（FDZL-FIX）：一项单臂、开放标签的2期临床研究

讲者：王辰辰 复旦大学附属肿瘤医院

26.　摘要号：344

标题：Nimotuzumab combined with chemotherapy plus immunotherapy as first-line treatment for advanced esophageal squamous cell carcinoma.

尼妥珠单抗联合化疗加免疫一线治疗晚期食管鳞状细胞癌

讲者：韩全利 中国人民解放军总医院第一医学中心

２7.　摘要号：361

标题：Preliminary results of the ALTER-E009 study: Efficacy and safety of anlotinib combined with radiotherapy in patients with locally advanced or metastatic esophageal squamous cell carcinoma (ESCC)—A multicenter, multi-cohort retrospective exploratory study.

ALTER-E009研究的初步结果：安罗替尼联合放疗治疗局部晚期或转移性食管鳞状细胞癌（ESCC）患者的疗效和安全性——一项多中心、多队列回顾性探索性研究

讲者：王鑫 中国医学科学院肿瘤医院

28.　摘要号：367

标题：Anlotinib combined with penpulimab and nab-paclitaxel as first-line treatment for advanced esophageal squamous cell carcinoma (ESCC): A single-arm, open-label phase II clinical trial.

安罗替尼联合penpulimab和白蛋白结合型紫杉醇作为晚期食管鳞状细胞癌 (ESCC) 一线治疗：一项单臂、开放标签Ⅱ期临床试验

讲者：常志伟 郑州大学第一附属医院

29.　摘要号：395

标题：Does chemotherapy regimen matter for first-line immunochemotherapy in low programmed cell death ligand 1 (PD-L1)-expressing esophageal squamous cell carcinoma (ESCC)? A systemic review and meta-analysis.

化疗方案在PD-L1低表达的食管鳞状细胞癌 (ESCC) 的一线免疫化疗中的作用：一项系统评价和荟萃分析

讲者：郭哲铨 台湾大学癌症中心

30.　摘要号：410

标题：Neoadjuvant SHR-1701 (a bifunctional anti-PD-L1/TGF-βRII agent) combined with chemoradiotherapy for resectable locally advanced esophageal squamous cell carcinoma (ESCC): A phase II trial.

新辅助 SHR-1701（双功能抗PD-L1/TGF-βRII药物）联合放化疗治疗局部可切除的晚期食管鳞状细胞癌 (ESCC)：一项Ⅱ期临床试验

讲者：刘成新 山东省肿瘤医院

31.　摘要号：411

标题：Bifunctional anti-PD-L1/TGF-βRII agent SHR-1701 plus chemotherapy as first-line treatment for advanced esophageal squamous cell carcinoma (ESCC): Survival results of a phase II trial.

双功能抗PD-L1/TGF-βRII药物SHR-1701联合化疗作为晚期食管鳞状细胞癌 (ESCC) 的一线治疗：一项Ⅱ期临床试验的生存结果

讲者：王艺 山东大学齐鲁医院

32.　摘要号：413

标题：Response characteristics of tislelizumab (TIS) plus chemotherapy (chemo) in first-line (1L) treatment of locally advanced or metastatic esophageal squamous cell carcinoma (ESCC): A post hoc analysis of RATIONALE-306.

替雷利珠单抗 (TIS) 联合化疗 (chemo) 在局部晚期或转移性食管鳞状细胞癌 (ESCC) 一线 (1L) 治疗中的反应特征：RATIONALE-306研究的事后分析

讲者：Li Yi 解放军总医院第五医学中心

33.　摘要号：421

标题：Perioperative adebrelimab combined with chemotherapy for locally advanced resectable esophageal squamous cell carcinoma: A single-arm, open-label, multicenter study.

围手术期阿得贝利单抗联合化疗治疗局部晚期可切除食管鳞状细胞癌：一项单臂、开放标签、多中心研究

讲者：戴亮 北京大学肿瘤医院

34.　摘要号：424

标题：An organ-preserving strategy in patients with esophageal squamous cell carcinoma treated with immunochemotherapy.

免疫化疗治疗食管鳞状细胞癌患者的器官保留策略

讲者：张博 中国医学科学院肿瘤医院

35.　摘要号：437

标题：Chemoimmunotherapy plus radiotherapy in advanced esophageal squamous-cell carcinoma.

化疗免疫疗法联合放疗治疗晚期食管鳞状细胞癌

讲者：聂可可 青岛市中心医院

36.　摘要号：443

标题：Neoadjuvant adebrelimab plus chemotherapy for resectable locally advanced esophageal squamous cell carcinoma: A phase 2 trial

新辅助阿得贝利单抗联合化疗治疗可切除局部晚期食管鳞状细胞癌的Ⅱ期临床试验

讲者：李志 上海市胸科医院

37.　摘要号：445

标题：Fruquintinib plus camrelizumab combined with paclitaxel liposome and nedaplatin as first-line treatment for advanced esophageal squamous cell carcinoma (ESCC): A single-arm, phase II clinical trial.

呋喹替尼加卡瑞利珠单抗联合紫杉醇脂质体和奈达铂作为晚期食管鳞状细胞癌（ESCC）一线治疗：一项单臂Ⅱ期临床试验

讲者：顾艳宏 南京医科大学第一附属医院

38.　摘要号：459

标题：Anlotinib plus benmelstobart as adjuvant therapy in patients with esophageal squamous cell carcinoma: A phase II clinical trial (ALTER-E005).

安罗替尼联合贝莫苏拜单抗辅助治疗食管鳞状细胞癌患者：一项Ⅱ期临床试验研究（ALTER-E005）

讲者：郭昌莹 江西省肿瘤医院

39.　摘要号：460

标题：Clinical study of radiotherapy combined with tegafur bolus synchronization in the treatment of inoperable elderly middle and advanced esophageal cancer.

放疗联合替加氟静脉推注同步治疗不可手术切除的老年中晚期食管癌的临床研究

讲者：赵茜茜 西安交通大学第二附属医院

40.　摘要号：463

标题：Efficacy, safety and DNA methylation analysis of cadonilimab combined with taxane and cisplatin as first-line treatment for advanced esophageal squamous cell carcinoma (ESCC): Updated results from an open-label, multicenter phase II trial (AK104-IIT-014).

卡度尼利单抗联合紫杉烷和顺铂作为晚期食管鳞状细胞癌（ESCC）一线治疗的疗效、安全性及DNA甲基化分析：一项开放标签、多中心Ⅱ期试验（AK104-IIT-014）的最新结果

讲者：瞿望 中国医学科学院肿瘤医院

41.　摘要号：488

标题：Use of immune repertoire sequencing analysis to detect differences in treatment responses for advanced esophageal squamous cell carcinoma treated with camrelizumab and platinum-based chemotherapy.

利用免疫谱系测序分析检测卡瑞利珠单抗联合铂类化疗治疗晚期食管鳞状细胞癌的治疗反应差异

讲者：赵军 长治市人民医院

42.　摘要号：TPS506

标题：Neoadjuvant cadonilimab plus anlotinib followed by surgery for locally advanced esophageal squamous cell carcinoma: A single arm, phase 2 trial.

局部晚期食管鳞状细胞癌术前新辅助治疗采用卡度尼利单抗联合安罗替尼后行手术治疗：一项单臂、Ⅱ期临床试验

讲者：翁文翰 北京大学人民医院

版权声明